84 result(s) found
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
https://www.zacks.com/stock/news/2200063/ionis-ions-out-licenses-europe-rights-for-hae-drug-to-otsuka?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200063
Dec 19, 2023 - Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.
0
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
https://www.zacks.com/stock/news/2195315/pharma-stock-roundup-abbv-to-buy-cere-jnj-s-2024-view-lly-nvs-get-fda-nod?cid=CS-ZC-FT-analyst_blog|stock_roundup-2195315
Dec 08, 2023 - AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
0
Novartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug
https://www.zacks.com/stock/news/2194094/novartis-nvs-gets-fda-nod-for-rare-blood-disorder-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2194094
Dec 06, 2023 - Novartis (NVS) obtains FDA approval for Fabhalta, the first oral monotherapy for treating adults with PNH.
0
What Makes Wolters Kluwer NV (WTKWY) a Good Fit for 'Trend Investing'
https://www.zacks.com/stock/news/2194044/what-makes-wolters-kluwer-nv-wtkwy-a-good-fit-for-trend-investing?cid=CS-ZC-FT-tale_of_the_tape|recent_price_strength_screen-2194044
Dec 06, 2023 - Wolters Kluwer NV (WTKWY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
0